Issue 2 · July 2, 2026 · 5 min read
Ozempic's Surprise Payoff: Partners and Paychecks
A 29% jump in romance, 27% in landing a job
The weight-loss shots may be doing more than shrinking waistlines: new numbers suggest they nudged people toward partners and paychecks. Also this week, a midlife blood marker that flags dementia decades early, and 370 drugs we already own that quietly touch aging (one of them a nasal spray). Here's what's worth knowing:
Healthspan over lifespan: Mayo Clinic doctors argued for judging care by "healthspan", the years you stay sharp, mobile, and independent, not just alive.
3.8 million qualify: The Medicare GLP-1 Bridge went live July 1, with an estimated 3.8 million people eligible for roughly $50-a-month weight-loss drugs.
Longevity drugs, or hype?: The New York Times weighed whether weight-loss shots double as anti-aging drugs; researchers are intrigued but call it far too soon.
Diet culture, disrupted: With about 1 in 10 Americans having tried a GLP-1, a Fortune op-ed argued fad diets are over and protein is the new obsession.
316 years of sisters: Three Brazilian sisters aged 109, 104, and 103 were named the world's oldest living sibling trio, and scientists are now studying their DNA.
A healthy dose of skepticism: A New Yorker essay weighed longevity's hype against the evidence, landing on the basics: moving, sleeping, and connection still do the heavy lifting.
Genes aren't the whole story: After a clean 71-gene cancer panel, Bryan Johnson noted it covers only the ~5-10% of cancers that are inherited, so screening still matters.
Featured
Ozempic's surprise upside: partners and paychecks
The drugs everyone's on for weight may be reshaping more than waistlines. A new working paper from Harvard economist Rebecca Diamond tracked what happened after people started a GLP-1, and the effects spilled well past the scale:
Partners: single women who started a GLP-1 were 29% more likely to find a partner.
Paychecks: among those not already working, employment rose 27% over about a year and a half.
The fine print: both were measured against similar women who wanted the drug but hadn't started, so the gains showed up where there was the most room to gain.
It reframes GLP-1s as broad life tools, not just weight drugs, and hints at how far a metabolic reset can ripple into work and relationships.
The honest read: it's an observational working paper, not yet peer-reviewed, and the author cautions it isn't proof of cause and effect. But it's a genuinely hopeful signal about where these drugs are taking people, and worth understanding before you start one.
More this week
An early midlife marker for dementia risk
Scientists reported that GDF15, a protein measurable in a blood draw, tracks with dementia risk decades before symptoms. Pooling more than 500,000 people across six long-running studies, they found higher GDF15 in midlife predicted more dementia later, and in older adults the signal was strong: elevated levels came with roughly 60% higher risk of dementia, the tie strongest for the vascular kind.
The caveats are real: this is an association, not proof the protein does the damage, and there's no GDF15 test your doctor orders today. But a genetics analysis pointed the same way, and it fits a wider push to catch brain decline early, while there's still time to act. Knowing your own numbers is where prevention starts.
The next longevity drug may already be on the shelf
Everyone in longevity is hunting for a new drug. A new map argues some of the best candidates may already be in the medicine cabinet. A team scored 6,442 approved and experimental drugs against the network of human aging genes, and 370 landed right next to the machinery of aging, including a real surprise: oxymetazoline, the active ingredient in the decongestant Afrin. Even everyday aspirin touched six hallmarks of aging.
It's a prediction, not a prescription: this is cell-stage work, and the map doesn't prove any of these slows human aging. But instead of inventing longevity drugs from scratch, it points back at the ones we already understand, already approved and on the shelf, as worth a serious second look. A longevity clinician can help you tell the proven from the promising.
On the radar
Mark July 23-24: the FDA's compounding advisory committee meets to weigh popular peptides, including BPC-157, TB-500, MOTS-c, and Semax, for the list compounding pharmacies are allowed to make. If any are in your stack, the outcome could change how you get them.
Go deeper at longevity.io